Metra Biosystems aims to raise $30 million in float
This article was originally published in Clinica
One of a spate of spring public offerings from the medtech and diagnostics sector, Metra Biosystems (US) is taking the plunge after submitting its bone resorption tests to the US FDA for 510(k) approval in April and May. The Californian company intends to sell three million shares to raise about $30 million net at an assumed IPO offering price of $11 before the end of June. Proceeds will be used to expand marketing, manufacturing capacity and fund clinical studies.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.